Clinical Specialty Index

Community Pharmacist Post-Discharge Review Finds Common But Under-Actioned Drug Problems
Analysis Geriatrics / Geriatric Pharmacy Hypothesis-generating Grade: Low

Community pharmacist reviews cut post-discharge errors in older adults by 30%.

Finerenone Slows eGFR Decline in Non-Diabetic CKD
Analysis Nephrology Practice-changing Grade: Moderate

FIND-CKD extends the kidney-protective role of finerenone from diabetic to non-diabetic chronic kidney disease, giving pharmacists a new evidence-based add-on to renin-angiotensin system blockade.

Cefiderocol Matches Standard Care in Gram-Negative Bloodstream Infection
Analysis Infectious Disease / Antimicrobials Confirmatory Grade: Moderate

The first randomised trial dedicated to cefiderocol for hospital-acquired and health-care-associated Gram-negative bloodstream infection shows non-inferiority but no superiority, with a concerning mortality signal in metallo-beta-lactamase producers.

GOLD 2026 COPD Strategy: Mepolizumab Enters the Algorithm
Guideline COPD Practice-changing Grade: Moderate

GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.

Resmetirom Efficacy Holds With GLP-1 or SGLT2 Background; Weight Loss Amplifies It
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate

Resmetirom shows promise in MASH, especially with weight loss.

Esketamine Monotherapy Shows Rapid Efficacy in Treatment-Resistant Depression
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Moderate

Esketamine offers new hope for treatment-resistant depression monotherapy.

Plasma p-tau217 Discriminates Early-Onset Alzheimer's in Real-World Clinic
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low

This real-world diagnostic study extends plasma p-tau217 validation to early-onset Alzheimer's disease and flags severe renal impairment as a false-positive risk relevant to biomarker interpretation.

KRAS Inhibitors Reshape the Treatment Landscape in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

KRAS: From 'undruggable' to potential target in pancreatic cancer.

Dual PD-L1/Galectin-9 CRISPR nanoparticles curb melanoma in mice
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

CRISPR-loaded nanoparticles boost immune response against cancer.

Factor XI Inhibitors Cut Bleeding but Raise Ischemic Stroke in AF
Analysis Cardiology / Anticoagulation Confirmatory Grade: Low

Factor XI inhibitors reduce bleeding but may affect stroke prevention in atrial fibrillation.

Semaglutide Improves MASH Histology in Phase 3 ESSENCE Interim
Analysis Endocrinology / Diabetes / Obesity Practice-changing Grade: High

Semaglutide shows promise in treating metabolic dysfunction-associated steatohepatitis.

Automated Plasma p-tau217 Accurately Detects Alzheimer Pathology Across Care Settings
Analysis Neurology / Neuropharmacology Practice-changing Grade: High

This multicohort validation gives neurology pharmacists concrete accuracy, cutoff, and workflow data for a scalable blood test that can gate amyloid-targeting therapy eligibility.

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline on ACS Management
Guideline Acute Coronary Syndrome Practice-changing Grade: Moderate

Reflects pivotal updates in antiplatelet strategy and secondary prevention for Acute Coronary Syndrome management.

Factor XI Antibody Abelacimab Cuts Bleeding Versus Rivaroxaban in AF
Analysis Cardiology / Anticoagulation Hypothesis-generating Grade: Moderate

Abelacimab cuts bleeding risk in atrial fibrillation patients.

OCEANIC-AF: Asundexian Fails Stroke Prevention Versus Apixaban
Analysis Cardiology / Anticoagulation Practice-changing Grade: Moderate

Asundexian falls short on stroke prevention in AFib but cuts bleeding.